TGFB2 and glaucoma: Small molecule inhibitor PirfenidoneTM (Azuma, 2012) has been approved for the treatment of IPF. TGF-β1 targeting mAbs have also been tested in human IPF patients (Voelker et al., 2017), and TGF-β2 mAbs have anti-scaring activity in human glaucoma patients (Mead et al., 2003).